Antonio Cubillo

3.0k total citations
88 papers, 1.1k citations indexed

About

Antonio Cubillo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Antonio Cubillo has authored 88 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 18 papers in Cancer Research. Recurrent topics in Antonio Cubillo's work include Colorectal Cancer Treatments and Studies (34 papers), Pancreatic and Hepatic Oncology Research (24 papers) and Cancer Genomics and Diagnostics (17 papers). Antonio Cubillo is often cited by papers focused on Colorectal Cancer Treatments and Studies (34 papers), Pancreatic and Hepatic Oncology Research (24 papers) and Cancer Genomics and Diagnostics (17 papers). Antonio Cubillo collaborates with scholars based in Spain, United States and France. Antonio Cubillo's co-authors include Jesús Rodríguez-Pascual, Manuel Hidalgo, Yolanda Quijano, Rafael Álvarez, Fernando López‐Ríos, Carlos Plaza, Pedro P. López‐Casas, E. Vicente, Elena García-García and Mariano Barbacid and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and British Journal of Cancer.

In The Last Decade

Antonio Cubillo

85 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Antonio Cubillo Spain	18	864	253	248	233	208	88	1.1k
Coraline Dubot France	15	883 1.0×	371 1.5×	277 1.1×	305 1.3×	232 1.1×	64	1.5k
Andrew Dean Australia	17	1.1k 1.3×	694 2.7×	198 0.8×	267 1.1×	262 1.3×	104	1.6k
Stacey Stein United States	18	802 0.9×	387 1.5×	260 1.0×	327 1.4×	315 1.5×	74	1.4k
Marc Polus Belgium	13	977 1.1×	301 1.2×	370 1.5×	232 1.0×	153 0.7×	46	1.2k
Zishuo I. Hu United States	11	748 0.9×	378 1.5×	225 0.9×	415 1.8×	217 1.0×	12	1.2k
Tyler P. Robin United States	17	608 0.7×	405 1.6×	272 1.1×	198 0.8×	330 1.6×	55	1.3k
Casey W. Williamson United States	13	376 0.4×	204 0.8×	146 0.6×	184 0.8×	301 1.4×	30	926
Schlomo Schneebaum Israel	17	574 0.7×	194 0.8×	232 0.9×	225 1.0×	164 0.8×	54	1.1k
John A. Conti United Kingdom	14	1.1k 1.3×	305 1.2×	619 2.5×	118 0.5×	189 0.9×	25	1.6k

Countries citing papers authored by Antonio Cubillo

Since Specialization

Citations

This map shows the geographic impact of Antonio Cubillo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Cubillo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Cubillo more than expected).

Fields of papers citing papers by Antonio Cubillo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Cubillo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Cubillo. The network helps show where Antonio Cubillo may publish in the future.

Co-authorship network of co-authors of Antonio Cubillo

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Cubillo. A scholar is included among the top collaborators of Antonio Cubillo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Cubillo. Antonio Cubillo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Elez, Élena, Antonio Cubillo, Pilar Alfonso, et al.. (2024). Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study. BMC Cancer. 24(1). 446–446. 2 indexed citations

Hernández, Gema, et al.. (2023). 932P Survival in patients with relapsed/metastatic head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab or cetuximab-based therapy: A real-worlddata study with the TriNetX platform. Annals of Oncology. 34. S587–S587. 2 indexed citations

Ferri, Valentina, Emilio Vicente, Yolanda Quijano, et al.. (2023). Light and shadow of watch-and-wait strategy in rectal cancer: oncological result, clinical outcomes, and cost-effectiveness analysis. International Journal of Colorectal Disease. 38(1). 277–277. 5 indexed citations

Bonvalot, Sylvie, Jay S. Wunder, Alessandro Gronchi, et al.. (2021). Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study. European Journal of Surgical Oncology. 47(8). 2166–2172. 33 indexed citations

Miguel, Maria J. de, Ana P. Gomes, Valentina Boni, et al.. (2021). Toxicity and antitumor activity of novel agents in elderly patients with cancer included in phase 1 studies. Investigational New Drugs. 39(6). 1694–1701. 1 indexed citations

Bordonaro, Roberto, Aitana Calvo, A. Auriemma, et al.. (2021). Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study. ESMO Open. 6(5). 100270–100270. 11 indexed citations

Gkika, Eleni, Anca - Ligia Grosu, Teresa Macarulla, et al.. (2021). O-16 HEPANOVA: Final efficacy and safety results from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma. Annals of Oncology. 32. S225–S225. 3 indexed citations

Capdevila, Jaume, Àlex Teulé, Carlos López, et al.. (2020). 1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601). Annals of Oncology. 31. S770–S771. 37 indexed citations

Miguel, Maria J. de, Irene Moreno, Valentina Boni, et al.. (2020). 592P A predictive score of antitumour activity of novel agents in cancer patients treated in early phase studies. Annals of Oncology. 31. S497–S497. 1 indexed citations

10.

Moreno, Irene, et al.. (2020). 1749P COVID-19 impact and predictive factors for mortality in cancer patients. Annals of Oncology. 31. S1021–S1021.

11.

Grosu, Anca - Ligia, Yann Touchefeu, Thomas Brunner, et al.. (2020). P-215 phase 2 HEPANOVA study of tumor treating fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC): Interim safety analysis. Annals of Oncology. 31. S160–S160. 2 indexed citations

12.

Ko, Andrew H., Antonio Cubillo, Madappa N. Kundranda, et al.. (2018). CARRIE: A randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer. Annals of Oncology. 29. viii720–viii720. 8 indexed citations

13.

Pelzer, Uwe, Jean‐Frédéric Blanc, Davide Melisi, et al.. (2017). Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. British Journal of Cancer. 116(10). 1247–1253. 22 indexed citations

14.

Ielpo, Benedetto, Riccardo Caruso, Hipólito Durán, et al.. (2017). A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma. Surgical Oncology. 26(4). 402–410. 57 indexed citations

15.

Hidalgo, Manuel, Roberto Pazo-Cid, Carmen Guillén‐Ponce, et al.. (2017). A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC). Annals of Oncology. 28. v212–v212. 7 indexed citations

16.

Hubner, Richard, Antonio Cubillo, Jean‐Frédéric Blanc, et al.. (2016). O-004 Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine. Annals of Oncology. 27. ii119–ii119. 2 indexed citations

17.

Pereira-Suárez, Ana Laura, et al.. (2010). Mixed paratesticular liposarcoma with osteosarcoma elements. Clinical & Translational Oncology. 12(2). 148–149. 3 indexed citations

18.

Vaquero, Javier, Carlos Andrés Galán-Vidal, & Antonio Cubillo. (2005). Intra-articular Traumatic Disorders of the Knee in Children and Adolescents. Clinical Orthopaedics and Related Research. 432(432). 97–106. 28 indexed citations

19.

Cubillo, Antonio, María Cornide, & Manuel González Barón. (2000). Cáncer de mama y embarazo. Conceptos actuales. Medicina Clínica. 115(2). 65–69. 3 indexed citations

20.

Cubillo, Antonio, Javier de Castro, Jaime Feliú, & Manuel González Barón. (2000). Estado actual del tratamiento de las metástasis hepáticas del cáncer colorrectal. Medicina Clínica. 114(13). 506–510. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact